Literature DB >> 1181403

Daunorubicin metabolites in human urine.

S Takanashi, N R Bachur.   

Abstract

We studied the human metabolism of daunorubicin (D) by isolating and identifying metabolites from urine which retained the specific fluorescence properties of D. Metabolites were extracted by adsorption to polystyrene polymeric sorbants, separated on silicic acid columns and purified by thin-layer chromatography. Structures were determined by comparative chromatography, infrared, fluorescence and mass spectroscopy, and enzymatic and chemical degradation. D metabolites identified were daunorubicinol, daunorubicinol aglycone, deoxydaunorubicin aglycone, deoxydaunorubicinol aglycone, demethyl deoxydaunorubicinol aglycone, deoxydaunorubicinol aglycone 13-O-beta-glucuronide, demethyl deoxydaunorubicinol aglycone 4-O-sulfate and demethyl deoxydaunorubicinol aglycone 4-O-beta-glucuronide. Other metabolites have been purified but not identified. Human metabolism of D involves carbonyl reduction, reductive glycosidic cleavage, O-demethylation, O-sulfation and O-glucuronidation. Since daunorubicinol has biochemical properties similar to D, the metabolites may contribute to the pharmacologic and toxicologic effects credited to D.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1181403

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.

Authors:  S D Averbuch; R E Clawson; N R Bachur; R L Felsted
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies.

Authors:  Kunio Fujiwara; Masashi Shin; David M Hougaard; Lars-Inge Larsson
Journal:  Histochem Cell Biol       Date:  2006-07-19       Impact factor: 4.304

5.  Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.

Authors:  Joseph B Katzenmeyer; Christopher V Eddy; Edgar A Arriaga
Journal:  Anal Chem       Date:  2010-10-01       Impact factor: 6.986

6.  Uptake and metabolism of daunorubicin by human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 8.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

Review 9.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

10.  Immunocytochemical studies on the distribution pattern of daunomycin in rat gastrointestinal tract.

Authors:  Koji Ohara; Masashi Shin; Hiromichi Nakamuta; Lars-Inge Larsson; David M Hougaard; Kunio Fujiwara
Journal:  Histochem Cell Biol       Date:  2007-07-28       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.